Literatur
Haas R et al (2022) Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trial. Cancer 128:2796–2805
Callegaro D et al (2021) Has the outcome for patients who undergo resection of primary retroperitoneal sarcoma changed over time? A study of time trends during the past 15 years. Ann Surg Oncol 28:1700–1709
Bonvalot S et al (2019) Survival benefit of the surgical management of retroperitoneal sarcoma in a reference center: a nationwide study of the French sarcoma group from the netSarc database. Ann Surg Oncol 26:2286–2293
Schmitz R, Adam MA, Blazer DG (2019) Overcoming a travel burden to high-volume centers for treatment of retroperitoneal sarcomas is associated with improved survival. World J Surg Onc 17:180
Keung EZ et al (2018) Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer 124:4495–4503
Pasquali S et al (2022) Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: a Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. Cancer 128:85–93
[S3 Guideline ‘Adult soft tissue sarcomas’]. Chirurg 93, 520 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
C. Yang, J. Jakob und C. Reissfelder geben an, dass kein Interessenkonflikt besteht.
Additional information
Hinweis des Verlags
Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Yang, C., Jakob, J. & Reissfelder, C. Neoadjuvante Chemotherapie in retroperitonealen Sarkomen. Chirurgie 95, 491–492 (2024). https://doi.org/10.1007/s00104-024-02099-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-024-02099-6